Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 1558.

https://doi.org/10.1182/blood-2019-128945

Published: 2019

Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Blood (2018) 132 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2018-99-111712

Published: 2018

Journal Articles

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Sigrid Dubois, PhD, Milos D. Miljkovic, MD, Thomas Fleisher, Jennifer Hsu, RN, Thomas A Waldmann, MD, Kevin C Conlon, MD

Blood (2017) 130 (Supplement 1): 3840.

https://doi.org/10.1182/blood.V130.Suppl_1.3840.3840

Published: 2017

Journal Articles

Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd

Lauren M. Curtis, MD, David Venzon, PhD, Fran T. Hakim, PhD, Edward W. Cowen, MD MHSc, Jennifer Hsu, RN, Licia Masuch, Jacqueline W. Mays, DDS, MHSc, PhD, Sandra A. Mitchell, CRNP, PhD AOCN, Filip Pirsl, Iskra Pusic, MD, Jeremy J. Rose, MS, Zoya J. Kuzmina, MD PhD, Kristin Baird, MD, Robert Peter Gale, Daniel H. Fowler, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 507.

https://doi.org/10.1182/blood.V128.22.507.507

Published: 2016

Journal Articles

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Jacqueline W. Mays, DDS, MHSc, PhD, Lauren M. Curtis, MD, Carol Bassim, DMD, MS, Seth M. Steinberg, PhD, David Venzon, PhD, Jeremy J. Rose, MS, Monica Cho, Christopher G. Kanakry, MD, Fahd Yazdanie, Daniele Avila, NP, Kristin Baird, MD, Jennifer Hsu, RN, Licia Masuch, George Grimes, RPh, Judith Starling, RPh, Daniel H. Fowler, MD, Ronald E. Gress, MD, Fran T. Hakim, PhD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 826.

https://doi.org/10.1182/blood.V128.22.826.826

Published: 2016

Journal Articles

Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis

Annie Im, MD, Frances T. Hakim, PhD, Filip Pirsl, Seth M. Steinberg, PhD, Lauren M. Curtis, MD, Sandra A. Mitchell, CRNP, PhD AOCN, Edward W. Cowen, MD MHSc, Jennifer Hsu, RN, Judy Baruffaldi, Licia Masuch, Juan C. Gea-Banacloche, MD, David C. Halverson, MD, Daniel H. Fowler, MD, Ronald E. Gress, MD, Steven Z. Pavletic, MD

Blood (2015) 126 (23): 1937.

https://doi.org/10.1182/blood.V126.23.1937.1937

Published: 2015

Journal Articles

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

Blood (2015) 126 (23): 65.

https://doi.org/10.1182/blood.V126.23.65.65

Published: 2015

Journal Articles

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Blood (2014) 124 (21): 1147.

https://doi.org/10.1182/blood.V124.21.1147.1147

Published: 2014

Journal Articles

Utility Of An Algorithm For Use Of Plerixafor In Filgrastim-based Hematopoietic Progenitor Cell Mobilization In Patients With Plasma Cell Myeloma Treated With Carfilzomib-Lenalidomide-Dexamethasone.

Susan F. Leitman, MD, Nishant Tageja, MD, Neha Korde, MD, Yu Ying Yau, RN, Sheila Phang, RN, Jennifer Hsu, RN, Kristin Cole, RN, Hanh Khuu, MD, Ola Landgren, MD, PhD, Claude Sportes, MD

Blood (2013) 122 (21): 906.

https://doi.org/10.1182/blood.V122.21.906.906

Published: 2013

Journal Articles

Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM)

Nishant Tageja, MD, Neha Korde, MD, Constance Yuan, MD, PhD, Kristen Cole, RN, Jennifer Hsu, RN, Sheila Phang, RN, Daniele N. Avila, CRNP, Tiffany Taylor, Marcia Mulquin, RN, Diamond Zuchlinski, RN, Hanh Khuu, MD, Maryalice Stetler-Stevenson, MD, PhD, Susan F. Leitman, MD, Ola Landgren, MD, PhD, Claude Sportes, MD

Blood (2013) 122 (21): 2030.

https://doi.org/10.1182/blood.V122.21.2030.2030

Published: 2013

Journal Articles

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Brian C. Shaffer, MD, Andrew Flynn, David Moorshead, Zach Powell, Jennifer Hsu, RN, Rachel B Salit, MD, Frances T. Hakim, PhD, Ronald E. Gress, MD, Michael Bishop, MD, Juan Gea-Banacloche, MD, Steven Z. Pavletic, MD

Blood (2013) 122 (21): 4580.

https://doi.org/10.1182/blood.V122.21.4580.4580

Published: 2013

Journal Articles

Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Brian C Shaffer, MD, Christine Tremblay, BS, Daniel Peaceman, BS, Jennifer Hsu, RN, BSN, Seth M. Steinberg, PhD, Marcela Uribe, CHS, Sharon Adams, CHS, Willy A. Flegel, MD, Steven Z. Pavletic, MD

Blood (2012) 120 (21): 4201.

https://doi.org/10.1182/blood.V120.21.4201.4201

Published: 2012

NARROW

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Final Results of a Randomized Phase 2 Trial Evaluating Lower-Dose Versus Higher-Dose Pomalidomide as Therapy for Corticosteroid-Refractory Chronic Gvhd

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Clinical and Immunologic Characteristics of Patients with Chronic Graft-Versus-Host Disease Persisting Seven or More Years after Diagnosis

Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial

FLT Imaging Reveals Kinetics and Biology of Engraftment after Myeloablative HSCT

Utility Of An Algorithm For Use Of Plerixafor In Filgrastim-based Hematopoietic Progenitor Cell Mobilization In Patients With Plasma Cell Myeloma Treated With Carfilzomib-Lenalidomide-Dexamethasone.

Carfilzomib and Bortezomib Containing Regimens Yield High Rates Of MRD Negative Autologous Hematopoietic Progenitor Cell (HPC) Grafts In Multiple Myeloma (MM) and High Risk Smoldering Myeloma (SMM)

Infectious Complications After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation With Or Without Alemtuzumab Based In Vivo Lymphocyte Depletion

Minor Histocompatibility Antigen Mismatch and Incidence of Graft Versus Host Disease, Event-Free, and Overall Survival in Patients Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only